Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries
- PMID: 17612463
- DOI: 10.1590/s1020-49892007000300002
Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries
Abstract
Objective: To estimate the health and economic burden of rotavirus gastroenteritis in hospital and outpatient settings in eight Latin American and Caribbean countries (Argentina, Brazil, Chile, Dominican Republic, Honduras, Mexico, Panama, and Venezuela).
Methods: An economic model was constructed using epidemiological data from published articles, national health administration studies, and country-specific cost estimates. For each of the eight countries, the model estimated the rotavirus outcomes for the 2003 birth cohort during the first five years of life. The main outcome measures included health care costs, transportation costs, lost wages, and disease burden expressed in disability-adjusted life years. Estimates were expressed in 2003 US dollars. All future costs and disability-adjusted life year estimates were discounted at a rate of 3%. Sensitivity analyses evaluated the impact of specific variables on the medical cost of treating rotavirus.
Results: For every 1,000 children born during 2003 in the eight Latin American and Caribbean countries studied here, we estimated that rotavirus gastroenteritis would result in an average of 246 outpatient visits, 24 hospitalizations, 0.6 deaths, and 7,971 US dollars in direct medical costs during their first five years of life. The incidence of rotavirus-associated outpatient visits and the cost of outpatient visits were predicted to have the largest impact on the total medical cost per child.
Conclusions: Rotavirus gastroenteritis is likely to result in substantial disease and economic burden to health systems in Latin American and Caribbean countries, and the foreseeable burden should be an important consideration in evaluating the cost-effectiveness of vaccination.
Similar articles
-
Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries.Rev Panam Salud Publica. 2007 Apr;21(4):205-16. doi: 10.1590/s1020-49892007000300003. Rev Panam Salud Publica. 2007. PMID: 17612464
-
The Hidden Health and Economic Burden of Rotavirus Gastroenteritis in Malaysia: An Estimation Using Multiple Data Sources.Pediatr Infect Dis J. 2016 Jun;35(6):601-6. doi: 10.1097/INF.0000000000001129. Pediatr Infect Dis J. 2016. PMID: 27008464
-
Systematic review of studies on rotavirus disease cost-of-illness and productivity loss in Latin America and the Caribbean.Vaccine. 2013 Jul 2;31 Suppl 3:C45-57. doi: 10.1016/j.vaccine.2013.05.031. Vaccine. 2013. PMID: 23777691 Review.
-
The health and economic burden of rotavirus disease in Belgium.Eur J Pediatr. 2008 Dec;167(12):1409-19. doi: 10.1007/s00431-008-0684-3. Epub 2008 Mar 4. Eur J Pediatr. 2008. PMID: 18317802
-
Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.J Infect Dis. 2009 Nov 1;200 Suppl 1:S16-27. doi: 10.1086/605026. J Infect Dis. 2009. PMID: 19817595 Review.
Cited by
-
The burden of pediatric diarrhea: a cross-sectional study of incurred costs and perceptions of cost among Bolivian families.BMC Public Health. 2013 Aug 2;13:708. doi: 10.1186/1471-2458-13-708. BMC Public Health. 2013. PMID: 23915207 Free PMC article.
-
Economic impact of a rotavirus vaccine in Brazil.J Health Popul Nutr. 2008 Dec;26(4):388-96. doi: 10.3329/jhpn.v26i4.1880. J Health Popul Nutr. 2008. PMID: 19069617 Free PMC article.
-
Diarrhoea-related hospitalizations in children before and after implementation of monovalent rotavirus vaccination in Mexico.Bull World Health Organ. 2014 Feb 1;92(2):117-25. doi: 10.2471/BLT.13.125286. Epub 2013 Nov 20. Bull World Health Organ. 2014. PMID: 24623905 Free PMC article.
-
Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.Pharmacoeconomics. 2011 Nov;29(11):989-1009. doi: 10.2165/11207210-000000000-00000. Pharmacoeconomics. 2011. PMID: 21988293 Review.
-
Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective.Vaccine. 2011 Sep 2;29(38):6704-11. doi: 10.1016/j.vaccine.2011.05.038. Vaccine. 2011. PMID: 21624421 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical